Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Infinitus (China) Company Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This prosecution involves 1 distinct examiner and is situated within 1 distinct art unit, indicating a precise focus for the company's current intellectual property efforts. With this 1 pending matter, the company's active engagement with the patent office is currently minimal but highly targeted. The involvement of 1 distinct examiner within 1 distinct art unit suggests that the technology being examined is specialized and does not overlap with other pharmaceutical categories.
The busiest examiner, SPAINE, ROBERT FRANKLIN, is assigned 1 busiest examiner pending action. Practitioners should focus on the specific feedback from this 1 examiner to advance the 1 pending office action toward allowance. Because the entire pending portfolio is concentrated under 1 distinct examiner, the applicant can develop a specific understanding of the examiner's perspective. This focused environment allows for resolving biotechnological claim issues without the distraction of competing deadlines or varying examiner requirements across other applications.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SPAINE, ROBERT FRANKLIN | 1 | 75.0% | +0.0% |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18421911 | MODIFIED PRESCRIPTION OF GANCAO XIEXIN DECOCTION AND USE THEREOF | SPAINE, ROBERT FRANKLIN | 1655 | §103 | Final Rejection | 45d overdue | Pending | Jan 24, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial